Total Payments
$347,736
2024 Payments
$49,037
Companies
26
Transactions
340
Medicare Patients
1,971
Medicare Billing
$266,347
Payment Breakdown by Category
Other$296,632 (85.3%)
Travel$27,437 (7.9%)
Research$8,843 (2.5%)
Consulting$7,920 (2.3%)
Food & Beverage$6,763 (1.9%)
Education$141.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $264,032 | 97 | 75.9% |
| Honoraria | $32,600 | 10 | 9.4% |
| Travel and Lodging | $27,437 | 89 | 7.9% |
| Unspecified | $8,843 | 7 | 2.5% |
| Consulting Fee | $7,920 | 5 | 2.3% |
| Food and Beverage | $6,763 | 128 | 1.9% |
| Education | $141.61 | 4 | 0.0% |
Payments by Type
General
$338,893
333 transactions
Research
$8,843
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacyclics LLC, An AbbVie Company | $124,469 | 125 | $0 (2023) |
| Janssen Biotech, Inc. | $61,754 | 51 | $0 (2023) |
| Genentech USA, Inc. | $50,770 | 42 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $34,859 | 26 | $0 (2024) |
| Celgene Corporation | $26,482 | 23 | $0 (2019) |
| Genmab U.S., Inc. | $16,574 | 12 | $0 (2024) |
| ABBVIE INC. | $12,083 | 12 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $9,755 | 9 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,643 | 1 | $0 (2019) |
| PFIZER INC. | $3,244 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,037 | 47 | Genmab U.S., Inc. ($16,574) |
| 2023 | $37,126 | 24 | Genentech USA, Inc. ($18,793) |
| 2022 | $61,934 | 39 | Pharmacyclics LLC, an AbbVie Company ($21,914) |
| 2021 | $39,815 | 30 | Pharmacyclics LLC, An AbbVie Company ($16,692) |
| 2020 | $8,400 | 8 | Janssen Biotech, Inc. ($4,500) |
| 2019 | $61,899 | 80 | Janssen Biotech, Inc. ($24,941) |
| 2018 | $42,330 | 56 | Pharmacyclics LLC, An AbbVie Company ($18,173) |
| 2017 | $47,196 | 56 | Pharmacyclics LLC, An AbbVie Company ($35,217) |
All Payment Transactions
340 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $608.75 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $39.63 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 11/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: Oncology | ||||||
| 10/11/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 10/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $439.95 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $121.36 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $602.63 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $273.89 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $164.82 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $14.36 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: Oncology | ||||||
| 08/01/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 07/26/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $124.37 | General |
| Category: Oncology | ||||||
| 06/04/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ELRANATAMAB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/15/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $1,719.37 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Honoraria | Cash or cash equivalent | $8,150.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT | Takeda Pharmaceuticals U.S.A., Inc. | $5,643 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,930 | 4 |
| ADCETRIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 458 | 815 | $181,374 | $56,338 |
| 2022 | 14 | 601 | 1,144 | $270,238 | $85,697 |
| 2021 | 8 | 479 | 876 | $229,598 | $77,733 |
| 2020 | 9 | 433 | 738 | $172,344 | $46,579 |
Total Patients
1,971
Total Services
3,573
Medicare Billing
$266,347
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 289 | $95,081 | $31,508 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 182 | 264 | $64,416 | $18,286 | 28.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 70 | $11,690 | $2,881 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $5,964 | $1,874 | 31.4% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Office | 2023 | 22 | 22 | $1,606 | $576.80 | 35.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 16 | 43 | $1,075 | $445.05 | 41.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 15 | 43 | $817.00 | $327.23 | 40.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 16 | 36 | $249.00 | $239.40 | 96.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 14 | 34 | $476.00 | $201.28 | 42.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 138 | 356 | $117,124 | $39,573 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 215 | 358 | $87,352 | $24,910 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $10,224 | $3,550 | 34.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 43 | $10,922 | $3,512 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $8,788 | $2,635 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 60 | $10,020 | $2,430 | 24.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 40 | $7,600 | $2,278 | 30.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 19 | $5,149 | $2,047 | 39.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $4,824 | $1,894 | 39.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 12 | 12 | $2,412 | $957.45 | 39.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $2,886 | $669.42 | 23.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 13 | 55 | $1,375 | $574.44 | 41.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 14 | 62 | $1,178 | $476.14 | 40.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 14 | 64 | $384.00 | $189.72 | 49.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 140 | 371 | $116,419 | $43,216 | 37.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 207 | 357 | $83,522 | $25,532 | 30.6% |
About Dr. Steven Schuster, M.D
Dr. Steven Schuster, M.D is a Internal Medicine healthcare provider based in Fort Collins, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467664136.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Schuster, M.D has received a total of $347,736 in payments from pharmaceutical and medical device companies, with $49,037 received in 2024. These payments were reported across 340 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($264,032).
As a Medicare-enrolled provider, Schuster has provided services to 1,971 Medicare beneficiaries, totaling 3,573 services with total Medicare billing of $266,347. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Fort Collins, CO
- Active Since 05/04/2007
- Last Updated 03/17/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1467664136
Products in Payments
- Imbruvica (Drug) $78,180
- IMBRUVICA (Drug) $68,126
- DARZALEX (Biological) $45,577
- XPOVIO (Drug) $34,859
- VENCLEXTA (Biological) $24,181
- Revlimid (Drug) $23,369
- Venclexta (Biological) $18,793
- Epkinly (Drug) $16,574
- EPKINLY (Drug) $12,069
- Rituxan (Biological) $7,701
- ELREXFIO (Drug) $1,930
- ADCETRIS (Biological) $1,459
- VYXEOS (Drug) $102.92
- EMPLICITI (Biological) $73.19
- Aranesp (Biological) $53.93
- Kyprolis (Biological) $52.87
- TECENTRIQ (Biological) $39.52
- GAZYVA (Biological) $35.79
- NovoSeven (Biological) $25.73
- clonoSEQ (Device) $22.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fort Collins
Dr. Justin Strote, M.d, M.D
Internal Medicine — Payments: $65,289
Internal Medicine $65,289
Jason Mayer, M.d, M.D
Internal Medicine — Payments: $41,797
Internal Medicine $41,797
Russell Heath, Md, MD
Internal Medicine — Payments: $9,459
Internal Medicine $9,459
Allison Schneider, D.o, D.O
Internal Medicine — Payments: $6,736
Internal Medicine $6,736
Dr. Alejandro Munoz, M.d, M.D
Internal Medicine — Payments: $6,564
Internal Medicine $6,564
David Katz, Md, MD
Internal Medicine — Payments: $5,428
Internal Medicine $5,428